Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Our mission is to discover new ways to improve and extend people’s lives. Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. That is our purpose.
Our global portfolio comprises approximately 1 000 molecules, covering all major therapeutic areas, which accounted for 2015 sales of USD 10.1 billion. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.
Our products reach more than 500 million patients and our aspiration is to reach one billion. Our broad portfolio is spearheaded by our global leadership position in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the foundation of global healthcare systems. We also run a broad range of targeted corporate responsibility programs to increase access to medicine, medical information and appropriate medical training for healthcare professionals.
Sandoz Canada is headquartered in Boucherville, Québec, Canada.
Sandoz from a Canadian standpoint
A true leader in its field, Sandoz Canada markets and distributes a wide range of generics, biosimilars and specialty products. Sandoz Canada covers all major therapeutic areas with its broad portfolio of off-patent medicines and works closely with commercial and scientific partners to maximize its collective contribution to society.
Our ambition is to position Sandoz Canada as THE leader in Biosimilars & Generics powered by our people, portfolio and pipeline to serve as a trusted partner to pharmacies, hospitals, physicians and payers.
The Novartis Commitment to Patients and Caregivers
We recognize the importance of patients and caregivers understanding what they can expect from Novartis.